Rick Lundberg

Rick Lundberg has 35 years of experience in the life sciences industry ranging from de novo ventures to leading global biopharma companies.

Prior to joining Eikonizo, from 2010 to 2021, Rick was SVP of Corporate Development & Finance at Navitor Pharmaceuticals. From 2006 to 2009, Rick was Director of Business Development at Targanta Therapeutics (NASDAQ: TARG; acquired by The Medicines Company). Prior to Targanta, Rick led therapeutics business development initiatives and managed the genomics services business at Celera Genomics (NASDAQ: CRA). Rick began his career at Biogen Inc (NASDAQ: BIIB) where he served for nearly a decade in a broad range of business roles including business development, program management, investor relations, sales and marketing.

Rick holds a BA in Biochemical Sciences from Harvard University.